Article
Technological advancements to study cellular signaling pathways in inherited retinal degenerative diseases.
Current opinion in pharmacology - 1 Oct 2021
Roy Akanksha, Hilhorst Riet, Groten John, Paquet-Durand François, Tomar Tushar
Abstract excerpt
Inherited retinal degenerative diseases (IRDs) are rare neurodegenerative disorders with mutations in hundreds of genes leading to vision loss, primarily owing to photoreceptor cell death. This genetic diversity is impeding development of effective treatment options. Gene-based therapies have resulted in the first FDA-approved drug (Luxturna) for RPE65-specific IRD. Although currently explored in clinical trials,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
